Search - tctmd.com

Displaying 1 - 20 of 54

Sort: Relevancy | Date

News Daily News

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

Caitlin E. Cox

October 22, 2025

News Daily News

Evolocumab Gains Expanded Indication for Primary Prevention

Michael O'Riordan

August 26, 2025

News Daily News

FDA Approves TAVI for Asymptomatic Patients With Severe Aortic Stenosis

Michael O'Riordan

May 01, 2025

News Daily News

Coverage and Use of Impella and Watchman: A Tale of Four Countries

Michael O'Riordan

March 04, 2025

News Daily News

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Michael O'Riordan

February 20, 2025

News Daily News

FDA Approves Varipulse Pulsed-Field Ablation System for AF

Michael O'Riordan

November 07, 2024

News Opinion CV Team Dispatch

June 2024 Dispatch for the CV Team

L.A. McKeown

June 01, 2024

News Daily News

FDA Grants MACE Reduction Indication for Semaglutide

Todd Neale

March 08, 2024

News Daily News

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Michael O'Riordan

February 23, 2024

News Daily News

FDA Grants Tirzepatide a New Indication for Obesity Management

L.A. McKeown

November 08, 2023

News Daily News

FDA Approves Paradise Renal Denervation System: What Comes Next?

Todd Neale

November 08, 2023

News Daily News

FDA Approves Colchicine for Decreasing CV Events

Caitlin E. Cox

June 20, 2023

News Daily News

Higher Annual TAVI Volumes Linked to Greater Use of Embolic Protection

L.A. McKeown

August 23, 2022

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

News Daily News

British Medical Groups Express Concern About Inclisiran Rollout

Michael O'Riordan

December 14, 2021

News Daily News

FDA Approves Portico TAVI Valve, Paving the Way for Third US Device

Shelley Wood

September 20, 2021

News Daily News

FDA Approves Finerenone for Adults With CKD and Type 2 Diabetes

Yael L. Maxwell

July 09, 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for March 2021

Shelley Wood

April 02, 2021

News Daily News

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Michael O'Riordan

March 03, 2021

News Daily News

Inclisiran Approved in Europe for Lowering LDL Cholesterol

Michael O'Riordan

December 11, 2020

Advertisement

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

Evolocumab Gains Expanded Indication for Primary Prevention

FDA Approves TAVI for Asymptomatic Patients With Severe Aortic Stenosis

Coverage and Use of Impella and Watchman: A Tale of Four Countries

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

FDA Approves Varipulse Pulsed-Field Ablation System for AF

June 2024 Dispatch for the CV Team

FDA Grants MACE Reduction Indication for Semaglutide

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

FDA Grants Tirzepatide a New Indication for Obesity Management

FDA Approves Paradise Renal Denervation System: What Comes Next?

FDA Approves Colchicine for Decreasing CV Events

Higher Annual TAVI Volumes Linked to Greater Use of Embolic Protection

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

British Medical Groups Express Concern About Inclisiran Rollout

FDA Approves Portico TAVI Valve, Paving the Way for Third US Device

FDA Approves Finerenone for Adults With CKD and Type 2 Diabetes

TCTMD’s Top 10 Most Popular Stories for March 2021

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Inclisiran Approved in Europe for Lowering LDL Cholesterol

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content